Search

Your search keyword '"Fisher, David E"' showing total 1,677 results
Start Over Author "Fisher, David E"
1,677 results on '"Fisher, David E"'

1. MITF regulates IDH1, NNT, and a transcriptional program protecting melanoma from reactive oxygen species

Author

Roider, Elisabeth, Lakatos, Alexandra I. T., McConnell, Alicia M., Wang, Poguang, Mueller, Alina, Kawakami, Akinori, Tsoi, Jennifer, Szabolcs, Botond L., Ascsillán, Anna A., Suita, Yusuke, Igras, Vivien, Lo, Jennifer A., Hsiao, Jennifer J., Lapides, Rebecca, Pál, Dorottya M. P., Lengyel, Anna S., Navarini, Alexander, Okazaki, Arimichi, Iliopoulos, Othon, Németh, István, Graeber, Thomas G., Zon, Leonard, Giese, Roger W., Kemeny, Lajos V., and Fisher, David E.

Published
2024
Full Text
View/download PDF

3. Commensal papillomavirus immunity preserves the homeostasis of highly mutated normal skin

Author

Son, Heehwa G., Ha, Dat Thinh, Xia, Yun, Li, Tiancheng, Blandin, Jasmine, Oka, Tomonori, Azin, Marjan, Conrad, Danielle N., Zhou, Can, Zeng, Yuhan, Hasegawa, Tatsuya, Strickley, John D., Messerschmidt, Jonathan L., Guennoun, Ranya, Erlich, Tal H., Shoemaker, Gregory L., Johnson, Luke H., Palmer, Kenneth E., Fisher, David E., Horn, Thomas D., Neel, Victor A., Nazarian, Rosalynn M., Joh, Joongho J., and Demehri, Shadmehr

Published
2025
Full Text
View/download PDF

5. Topical therapy for regression and melanoma prevention of congenital giant nevi.

Author

Choi, Yeon Sook, Erlich, Tal H, von Franque, Max, Rachmin, Inbal, Flesher, Jessica L, Schiferle, Erik B, Zhang, Yi, Pereira da Silva, Marcello, Jiang, Alva, Dobry, Allison S, Su, Mack, Germana, Sharon, Lacher, Sebastian, Freund, Orly, Feder, Ezra, Cortez, Jose L, Ryu, Suyeon, Babila Propp, Tamar, Samuels, Yedidyah Leo, Zakka, Labib R, Azin, Marjan, Burd, Christin E, Sharpless, Norman E, Liu, X Shirley, Meyer, Clifford, Austen, William Gerald, Bojovic, Branko, Cetrulo, Curtis L, Mihm, Martin C, Hoon, Dave S, Demehri, Shadmehr, Hawryluk, Elena B, and Fisher, David E

Subjects
Animals, Humans, Mice, Melanoma, Nevus, Pigmented, Skin Neoplasms, Neoplasm Transplantation, Heterografts, Nras, congenital melanocytic nevus, hapten, melanoma, mole, prevention, topical, Pediatric, Biotechnology, Cancer, Clinical Research, Prevention, Biological Sciences, Medical and Health Sciences, Developmental Biology
Abstract

Giant congenital melanocytic nevi are NRAS-driven proliferations that may cover up to 80% of the body surface. Their most dangerous consequence is progression to melanoma. This risk often triggers preemptive extensive surgical excisions in childhood, producing severe lifelong challenges. We have presented preclinical models, including multiple genetically engineered mice and xenografted human lesions, which enabled testing locally applied pharmacologic agents to avoid surgery. The murine models permitted the identification of proliferative versus senescent nevus phases and treatments targeting both. These nevi recapitulated the histologic and molecular features of human giant congenital nevi, including the risk of melanoma transformation. Cutaneously delivered MEK, PI3K, and c-KIT inhibitors or proinflammatory squaric acid dibutylester (SADBE) achieved major regressions. SADBE triggered innate immunity that ablated detectable nevocytes, fully prevented melanoma, and regressed human giant nevus xenografts. These findings reveal nevus mechanistic vulnerabilities and suggest opportunities for topical interventions that may alter the therapeutic options for children with congenital giant nevi.

Published
2022

7. DrugMap: A quantitative pan-cancer analysis of cysteine ligandability

Author

Takahashi, Mariko, Chong, Harrison B., Zhang, Siwen, Yang, Tzu-Yi, Lazarov, Matthew J., Harry, Stefan, Maynard, Michelle, Hilbert, Brendan, White, Ryan D., Murrey, Heather E., Tsou, Chih-Chiang, Vordermark, Kira, Assaad, Jonathan, Gohar, Magdy, Dürr, Benedikt R., Richter, Marianne, Patel, Himani, Kryukov, Gregory, Brooijmans, Natasja, Alghali, Aliyu Sidi Omar, Rubio, Karla, Villanueva, Antonio, Zhang, Junbing, Ge, Maolin, Makram, Farah, Griesshaber, Hanna, Harrison, Drew, Koglin, Ann-Sophie, Ojeda, Samuel, Karakyriakou, Barbara, Healy, Alexander, Popoola, George, Rachmin, Inbal, Khandelwal, Neha, Neil, Jason R., Tien, Pei-Chieh, Chen, Nicholas, Hosp, Tobias, van den Ouweland, Sanne, Hara, Toshiro, Bussema, Lillian, Dong, Rui, Shi, Lei, Rasmussen, Martin Q., Domingues, Ana Carolina, Lawless, Aleigha, Fang, Jacy, Yoda, Satoshi, Nguyen, Linh Phuong, Reeves, Sarah Marie, Wakefield, Farrah Nicole, Acker, Adam, Clark, Sarah Elizabeth, Dubash, Taronish, Kastanos, John, Oh, Eugene, Fisher, David E., Maheswaran, Shyamala, Haber, Daniel A., Boland, Genevieve M., Sade-Feldman, Moshe, Jenkins, Russell W., Hata, Aaron N., Bardeesy, Nabeel M., Suvà, Mario L., Martin, Brent R., Liau, Brian B., Ott, Christopher J., Rivera, Miguel N., Lawrence, Michael S., and Bar-Peled, Liron

Published
2024
Full Text
View/download PDF

8. B-cell-specific checkpoint molecules that regulate anti-tumour immunity

Author

Bod, Lloyd, Kye, Yoon-Chul, Shi, Jingwen, Torlai Triglia, Elena, Schnell, Alexandra, Fessler, Johannes, Ostrowski, Stephen M., Von-Franque, Max Y., Kuchroo, Juhi R., Barilla, Rocky M., Zaghouani, Sarah, Christian, Elena, Delorey, Toni Marie, Mohib, Kanishka, Xiao, Sheng, Slingerland, Nadine, Giuliano, Christopher J., Ashenberg, Orr, Li, Zhaorong, Rothstein, David M., Fisher, David E., Rozenblatt-Rosen, Orit, Sharpe, Arlene H., Quintana, Francisco J., Apetoh, Lionel, Regev, Aviv, and Kuchroo, Vijay K.

Published
2023
Full Text
View/download PDF

9. The State of Melanoma: Emergent Challenges and Opportunities

Author

Atkins, Michael B, Curiel-Lewandrowski, Clara, Fisher, David E, Swetter, Susan M, Tsao, Hensin, Aguirre-Ghiso, Julio A, Soengas, Maria S, Weeraratna, Ashani T, Flaherty, Keith T, Herlyn, Meenhard, Sosman, Jeffrey A, Tawbi, Hussein A, Pavlick, Anna C, Cassidy, Pamela B, Chandra, Sunandana, Chapman, Paul B, Daud, Adil, Eroglu, Zeynep, Ferris, Laura K, Fox, Bernard A, Gershenwald, Jeffrey E, Gibney, Geoffrey T, Grossman, Douglas, Hanks, Brent A, Hanniford, Douglas, Hernando, Eva, Jeter, Joanne M, Johnson, Douglas B, Khleif, Samir N, Kirkwood, John M, Leachman, Sancy A, Mays, Darren, Nelson, Kelly C, Sondak, Vernon K, Sullivan, Ryan J, Merlino, Glenn, and Foundation, on behalf of the Melanoma Research

Subjects
Prevention, Cancer, Biomedical Research, COVID-19, Humans, Medical Oncology, Melanoma, Practice Guidelines as Topic, SARS-CoV-2, Skin Neoplasms, Melanoma Research Foundation, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Five years ago, the Melanoma Research Foundation (MRF) conducted an assessment of the challenges and opportunities facing the melanoma research community and patients with melanoma. Since then, remarkable progress has been made on both the basic and clinical research fronts. However, the incidence, recurrence, and death rates for melanoma remain unacceptably high and significant challenges remain. Hence, the MRF Scientific Advisory Council and Breakthrough Consortium, a group that includes clinicians and scientists, reconvened to facilitate intensive discussions on thematic areas essential to melanoma researchers and patients alike, prevention, detection, diagnosis, metastatic dormancy and progression, response and resistance to targeted and immune-based therapy, and the clinical consequences of COVID-19 for patients with melanoma and providers. These extensive discussions helped to crystalize our understanding of the challenges and opportunities facing the broader melanoma community today. In this report, we discuss the progress made since the last MRF assessment, comment on what remains to be overcome, and offer recommendations for the best path forward.

Published
2021

10. Functional genomics of human clear cell sarcoma: genomic, transcriptomic and chemical biology landscape for clear cell sarcoma

Author

Rasmussen, Samuel V., Wozniak, Agnieszka, Lathara, Melvin, Goldenberg, Joshua M., Samudio, Benjamin M., Bickford, Lissett R., Nagamori, Kiyo, Wright, Hollis, Woods, Andrew D., Chauhan, Shefali, Lee, Che-Jui, Rudzinski, Erin R., Swift, Michael K., Kondo, Tadashi, Fisher, David E., Imyanitov, Evgeny, Machado, Isidro, Llombart-Bosch, Antonio, Andrulis, Irene L., Gokgoz, Nalan, Wunder, Jay, Mirotaki, Hiroshi, Nakamura, Takuro, Srinivasa, Ganapati, Thway, Khin, Jones, Robin L., Huang, Paul H., Berlow, Noah E., Schöffski, Patrick, and Keller, Charles

Published
2023
Full Text
View/download PDF

13. Targeting TBK1 to overcome resistance to cancer immunotherapy

Author

Sun, Yi, Revach, Or-yam, Anderson, Seth, Kessler, Emily A., Wolfe, Clara H., Jenney, Anne, Mills, Caitlin E., Robitschek, Emily J., Davis, Thomas G. R., Kim, Sarah, Fu, Amina, Ma, Xiang, Gwee, Jia, Tiwari, Payal, Du, Peter P., Sindurakar, Princy, Tian, Jun, Mehta, Arnav, Schneider, Alexis M., Yizhak, Keren, Sade-Feldman, Moshe, LaSalle, Thomas, Sharova, Tatyana, Xie, Hongyan, Liu, Shuming, Michaud, William A., Saad-Beretta, Rodrigo, Yates, Kathleen B., Iracheta-Vellve, Arvin, Spetz, Johan K. E., Qin, Xingping, Sarosiek, Kristopher A., Zhang, Gao, Kim, Jong Wook, Su, Mack Y., Cicerchia, Angelina M., Rasmussen, Martin Q., Klempner, Samuel J., Juric, Dejan, Pai, Sara I., Miller, David M., Giobbie-Hurder, Anita, Chen, Jonathan H., Pelka, Karin, Frederick, Dennie T., Stinson, Susanna, Ivanova, Elena, Aref, Amir R., Paweletz, Cloud P., Barbie, David A., Sen, Debattama R., Fisher, David E., Corcoran, Ryan B., Hacohen, Nir, Sorger, Peter K., Flaherty, Keith T., Boland, Genevieve M., Manguso, Robert T., and Jenkins, Russell W.

Published
2023
Full Text
View/download PDF

14. Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses

Author

Lo, Jennifer A, Kawakubo, Masayoshi, Juneja, Vikram R, Su, Mack Y, Erlich, Tal H, LaFleur, Martin W, Kemeny, Lajos V, Rashid, Mamunur, Malehmir, Mohsen, Rabi, S Alireza, Raghavan, Rumya, Allouche, Jennifer, Kasumova, Gyulnara, Frederick, Dennie T, Pauken, Kristen E, Weng, Qing Yu, Pereira da Silva, Marcelo, Xu, Yu, van der Sande, Anita AJ, Silkworth, Whitney, Roider, Elisabeth, Browne, Edward P, Lieb, David J, Wang, Belinda, Garraway, Levi A, Wu, Catherine J, Flaherty, Keith T, Brinckerhoff, Constance E, Mullins, David W, Adams, David J, Hacohen, Nir, Hoang, Mai P, Boland, Genevieve M, Freeman, Gordon J, Sharpe, Arlene H, Manstein, Dieter, and Fisher, David E

Subjects
Cancer, Animals, Antigens, Neoplasm, Epitopes, Humans, Immune Checkpoint Inhibitors, Melanocytes, Melanoma, Mice, Biological Sciences, Medical and Health Sciences
Abstract

Although immune checkpoint inhibitors (ICIs), such as anti-programmed cell death protein-1 (PD-1), can deliver durable antitumor effects, most patients with cancer fail to respond. Recent studies suggest that ICI efficacy correlates with a higher load of tumor-specific neoantigens and development of vitiligo in patients with melanoma. Here, we report that patients with low melanoma neoantigen burdens who responded to ICI had tumors with higher expression of pigmentation-related genes. Moreover, expansion of peripheral blood CD8+ T cell populations specific for melanocyte antigens was observed only in patients who responded to anti-PD-1 therapy, suggesting that ICI can promote breakdown of tolerance toward tumor-lineage self-antigens. In a mouse model of poorly immunogenic melanomas, spreading of epitope recognition toward wild-type melanocyte antigens was associated with markedly improved anti-PD-1 efficacy in two independent approaches: introduction of neoantigens by ultraviolet (UV) B radiation mutagenesis or the therapeutic combination of ablative fractional photothermolysis plus imiquimod. Complete responses against UV mutation-bearing tumors after anti-PD-1 resulted in protection from subsequent engraftment of melanomas lacking any shared neoantigens, as well as pancreatic adenocarcinomas forcibly overexpressing melanocyte-lineage antigens. Our data demonstrate that somatic mutations are sufficient to provoke strong antitumor responses after checkpoint blockade, but long-term responses are not restricted to these putative neoantigens. Epitope spreading toward T cell recognition of wild-type tumor-lineage self-antigens represents a common pathway for successful response to ICI, which can be evoked in neoantigen-deficient tumors by combination therapy with ablative fractional photothermolysis and imiquimod.

Published
2021

15. A unique hyperdynamic dimer interface permits small molecule perturbation of the melanoma oncoprotein MITF for melanoma therapy

Author

Liu, Zaizhou, Chen, Kaige, Dai, Jun, Xu, Peng, Sun, Wei, Liu, Wanlin, Zhao, Zhixin, Bennett, Steven P., Li, Peifeng, Ma, Tiancheng, Lin, Yuqi, Kawakami, Akinori, Yu, Jing, Wang, Fei, Wang, Chunxi, Li, Miao, Chase, Peter, Hodder, Peter, Spicer, Timothy P., Scampavia, Louis, Cao, Chunyang, Pan, Lifeng, Dong, Jiajia, Chen, Yong, Yu, Biao, Guo, Min, Fang, Pengfei, Fisher, David E., and Wang, Jing

Published
2023
Full Text
View/download PDF

16. NRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancer

Author

Weiss-Sadan, Tommy, Ge, Maolin, Hayashi, Makiko, Gohar, Magdy, Yao, Cong-Hui, de Groot, Adriaan, Harry, Stefan, Carlin, Alexander, Fischer, Hannah, Shi, Lei, Wei, Ting-Yu, Adelmann, Charles H., Wolf, Konstantin, Vornbäumen, Tristan, Dürr, Benedikt R., Takahashi, Mariko, Richter, Marianne, Zhang, Junbing, Yang, Tzu-Yi, Vijay, Vindhya, Fisher, David E., Hata, Aaron N., Haigis, Marcia C., Mostoslavsky, Raul, Bardeesy, Nabeel, Papagiannakopoulos, Thales, and Bar-Peled, Liron

Published
2023
Full Text
View/download PDF

17. Erratum: Jeter JM, Bowles TL, Curiel‐Lewandrowski C, et al. Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer. 2019:125:18‐44.

Author

Jeter, Joanne M, Bowles, Tawnya L, Curiel-Lewandrowski, Clara, Swetter, Susan M, Filipp, Fabian V, Abdel-Malek, Zalfa A, Geskin, Larisa J, Brewer, Jerry D, Arbiser, Jack L, Gershenwald, Jeffrey E, Chu, Emily Y, Kirkwood, John M, Box, Neil F, Funchain, Pauline, Fisher, David E, Kendra, Kari L, Marghoob, Ashfaq A, Chen, Suephy C, Ming, Michael E, Albertini, Mark R, Vetto, John T, Margolin, Kim A, Pagoto, Sherry L, Hay, Jennifer L, Grossman, Douglas, Ellis, Darrel L, Kashani-Sabet, Mohammed, Mangold, Aaron R, Markovic, Svetomir N, Meyskens, Frank L Jr, Nelson, Kelly C, Powers, Jennifer G, Robinson, June K, Sahni, Debjani, Sekulic, Aleksandar, Sondak, Vernon K, Wei, Maria L, Zager, Jonathan S, Dellavalle, Robert P, Thompson, John A, Weinstock, Martin A, Leachman, Sancy A, and Cassidy, Pamela B

Subjects
Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Published
2019

18. Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials

Author

Jeter, Joanne M, Bowles, Tawnya L, Curiel-Lewandrowski, Clara, Swetter, Susan M, Filipp, Fabian V, Abdel-Malek, Zalfa A, Geskin, Larisa J, Brewer, Jerry D, Arbiser, Jack L, Gershenwald, Jeffrey E, Chu, Emily Y, Kirkwood, John M, Box, Neil F, Funchain, Pauline, Fisher, David E, Kendra, Kari L, Marghoob, Ashfaq A, Chen, Suephy C, Ming, Michael E, Albertini, Mark R, Vetto, John T, Margolin, Kim A, Pagoto, Sherry L, Hay, Jennifer L, Grossman, Douglas, Ellis, Darrel L, Kashani-Sabet, Mohammed, Mangold, Aaron R, Markovic, Svetomir N, Meyskens, Frank L, Nelson, Kelly C, Powers, Jennifer G, Robinson, June K, Sahni, Debjani, Sekulic, Aleksandar, Sondak, Vernon K, Wei, Maria L, Zager, Jonathan S, Dellavalle, Robert P, Thompson, John A, Weinstock, Martin A, Leachman, Sancy A, and Cassidy, Pamela B

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Prevention, Clinical Trials and Supportive Activities, Cancer, 5.1 Pharmaceuticals, 6.1 Pharmaceuticals, 3.3 Nutrition and chemoprevention, 6.9 Resources and infrastructure (treatment evaluation), Animals, Anticarcinogenic Agents, Chemoprevention, Clinical Trials, Phase III as Topic, Drug Development, Drug Repositioning, Female, Humans, Male, Melanoma, Radiation-Protective Agents, Skin Neoplasms, biomarkers, chemoprevention, human model systems, melanoma, natural products, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Public health
Abstract

Recent progress in the treatment of advanced melanoma has led to unprecedented improvements in overall survival and, as these new melanoma treatments have been developed and deployed in the clinic, much has been learned about the natural history of the disease. Now is the time to apply that knowledge toward the design and clinical evaluation of new chemoprevention agents. Melanoma chemoprevention has the potential to reduce dramatically both the morbidity and the high costs associated with treating patients who have metastatic disease. In this work, scientific and clinical melanoma experts from the national Melanoma Prevention Working Group, composed of National Cancer Trials Network investigators, discuss research aimed at discovering and developing (or repurposing) drugs and natural products for the prevention of melanoma and propose an updated pipeline for translating the most promising agents into the clinic. The mechanism of action, preclinical data, epidemiological evidence, and results from available clinical trials are discussed for each class of compounds. Selected keratinocyte carcinoma chemoprevention studies also are considered, and a rationale for their inclusion is presented. These data are summarized in a table that lists the type and level of evidence available for each class of agents. Also included in the discussion is an assessment of additional research necessary and the likelihood that a given compound may be a suitable candidate for a phase 3 clinical trial within the next 5 years.

Published
2019

20. CYP27A1-dependent anti-melanoma activity of limonoid natural products targets mitochondrial metabolism

Author

Cho, Hyelim, Shen, Qiong, Zhang, Lydia H., Okumura, Mikiko, Kawakami, Akinori, Ambrose, Jessi, Sigoillot, Frederic, Miller, Howard R., Gleim, Scott, Cobos-Correa, Amanda, Wang, Ying, Piechon, Philippe, Roma, Guglielmo, Eggimann, Fabian, Moore, Charles, Aspesi, Peter, Jr., Mapa, Felipa A., Burks, Heather, Ross, Nathan T., Krastel, Philipp, Hild, Marc, Maimone, Thomas J., Fisher, David E., Nomura, Daniel K., Tallarico, John A., Canham, Stephen M., Jenkins, Jeremy L., and Forrester, William C.

Published
2021
Full Text
View/download PDF

21. NNT mediates redox-dependent pigmentation via a UVB- and MITF-independent mechanism

Author

Allouche, Jennifer, Rachmin, Inbal, Adhikari, Kaustubh, Pardo, Luba M., Lee, Ju Hee, McConnell, Alicia M., Kato, Shinichiro, Fan, Shaohua, Kawakami, Akinori, Suita, Yusuke, Wakamatsu, Kazumasa, Igras, Vivien, Zhang, Jianming, Navarro, Paula P., Lugo, Camila Makhlouta, Noonan, Haley R., Christie, Kathleen A., Itin, Kaspar, Mujahid, Nisma, Lo, Jennifer A., Won, Chong Hyun, Evans, Conor L., Weng, Qing Yu, Wang, Hequn, Osseiran, Sam, Lovas, Alyssa, Németh, István, Cozzio, Antonio, Navarini, Alexander A., Hsiao, Jennifer J., Nguyen, Nhu, Kemény, Lajos V., Iliopoulos, Othon, Berking, Carola, Ruzicka, Thomas, Gonzalez-José, Rolando, Bortolini, Maria-Cátira, Canizales-Quinteros, Samuel, Acuna-Alonso, Victor, Gallo, Carla, Poletti, Giovanni, Bedoya, Gabriel, Rothhammer, Francisco, Ito, Shosuke, Schiaffino, Maria Vittoria, Chao, Luke H., Kleinstiver, Benjamin P., Tishkoff, Sarah, Zon, Leonard I., Nijsten, Tamar, Ruiz-Linares, Andrés, Fisher, David E., and Roider, Elisabeth

Published
2021
Full Text
View/download PDF

22. Artificial Intelligence Approach in Melanoma

Author

Curiel-Lewandrowski, Clara, Novoa, Roberto A., Berry, Elizabeth, Celebi, M. Emre, Codella, Noel, Giuste, Felipe, Gutman, David, Halpern, Allan, Leachman, Sancy, Liu, Yuan, Liu, Yun, Reiter, Ofer, Tschandl, Philipp, Fisher, David E., Section editor, Hayward, Nick, Section editor, Whiteman, David C., Section editor, Flaherty, Keith T., Section editor, Hodi, F. Stephen, Section editor, Tsao, Hensin, Section editor, Merlino, Glenn, Section editor, Fisher, David E., editor, and Bastian, Boris C., editor

Published
2019
Full Text
View/download PDF

23. Melanoma Immunology and Immunotherapy

Author

Sullivan, Ryan J., Hodi, F. Stephen, Fisher, David E., Section editor, Hayward, Nick, Section editor, Whiteman, David C., Section editor, Flaherty, Keith T., Section editor, Tsao, Hensin, Section editor, Merlino, Glenn, Section editor, Fisher, David E., editor, and Bastian, Boris C., editor

Published
2019
Full Text
View/download PDF

24. The Biology of Pigmentation

Author

Dobry, Allison S., Fisher, David E., Hayward, Nick, Section editor, Whiteman, David C., Section editor, Flaherty, Keith T., Section editor, Hodi, F. Stephen, Section editor, Tsao, Hensin, Section editor, Merlino, Glenn, Section editor, Fisher, David E., editor, and Bastian, Boris C., editor

Published
2019
Full Text
View/download PDF

25. Principles of Targeted Therapy

Author

Bollag, Gideon, Flaherty, Keith T., Fisher, David E., Section editor, Hayward, Nick, Section editor, Whiteman, David C., Section editor, Hodi, F. Stephen, Section editor, Tsao, Hensin, Section editor, Merlino, Glenn, Section editor, Fisher, David E., editor, and Bastian, Boris C., editor

Published
2019
Full Text
View/download PDF

26. Microbiome and Melanoma

Author

Arora, Reetakshi, Hermann, Amanda, Wargo, Jennifer A., Fisher, David E., Section editor, Hayward, Nick, Section editor, Whiteman, David C., Section editor, Flaherty, Keith T., Section editor, Hodi, F. Stephen, Section editor, Tsao, Hensin, Section editor, Merlino, Glenn, Section editor, Fisher, David E., editor, and Bastian, Boris C., editor

Published
2019
Full Text
View/download PDF

27. Epigenetic Regulation in Melanoma

Author

Dang, Michelle, Zon, Leonard, Fisher, David E., Section editor, Hayward, Nick, Section editor, Whiteman, David C., Section editor, Flaherty, Keith T., Section editor, Hodi, F. Stephen, Section editor, Tsao, Hensin, Section editor, Merlino, Glenn, Section editor, Fisher, David E., editor, and Bastian, Boris C., editor

Published
2019
Full Text
View/download PDF

28. Epidemiology of Melanocytic Neoplasia

Author

Tucker, Margaret Anne, Fisher, David E., Section editor, Hayward, Nick, Section editor, Whiteman, David C., Section editor, Flaherty, Keith T., Section editor, Hodi, F. Stephen, Section editor, Tsao, Hensin, Section editor, Merlino, Glenn, Section editor, Fisher, David E., editor, and Bastian, Boris C., editor

Published
2019
Full Text
View/download PDF

29. Inherited Contributions to Melanoma Risk

Author

Brown, Kevin M., MacGregor, Stuart, Law, Matthew H., Fisher, David E., Section editor, Hayward, Nick, Section editor, Whiteman, David C., Section editor, Flaherty, Keith T., Section editor, Hodi, F. Stephen, Section editor, Tsao, Hensin, Section editor, Merlino, Glenn, Section editor, Fisher, David E., editor, and Bastian, Boris C., editor

Published
2019
Full Text
View/download PDF

30. Melanoma Metabolism

Author

Baenke, Franziska, Dhomen, Nathalie, Gottlieb, Eyal, Marais, Richard, Fisher, David E., Section editor, Hayward, Nick, Section editor, Whiteman, David C., Section editor, Flaherty, Keith T., Section editor, Hodi, F. Stephen, Section editor, Tsao, Hensin, Section editor, Merlino, Glenn, Section editor, Fisher, David E., editor, and Bastian, Boris C., editor

Published
2019
Full Text
View/download PDF

31. Prevention of Cutaneous Melanoma

Author

Sinclair, Craig, Wilson, Louise F., Olsen, Catherine, Nicholson, Anna, Fisher, David E., Section editor, Hayward, Nick, Section editor, Whiteman, David C., Section editor, Flaherty, Keith T., Section editor, Hodi, F. Stephen, Section editor, Tsao, Hensin, Section editor, Merlino, Glenn, Section editor, Fisher, David E., editor, and Bastian, Boris C., editor

Published
2019
Full Text
View/download PDF

32. Animal Models of Melanoma

Author

Aktary, Zackie, McMahon, Martin, Larue, Lionel, Fisher, David E., Section editor, Hayward, Nick, Section editor, Whiteman, David C., Section editor, Flaherty, Keith T., Section editor, Hodi, F. Stephen, Section editor, Tsao, Hensin, Section editor, Merlino, Glenn, Section editor, Fisher, David E., editor, and Bastian, Boris C., editor

Published
2019
Full Text
View/download PDF

33. Molecular Genetics of Melanocytic Neoplasia

Author

Hodis, Eran, Garraway, Levi A., Fisher, David E., Section editor, Hayward, Nick, Section editor, Whiteman, David C., Section editor, Flaherty, Keith T., Section editor, Hodi, F. Stephen, Section editor, Tsao, Hensin, Section editor, Merlino, Glenn, Section editor, Fisher, David E., editor, and Bastian, Boris C., editor

Published
2019
Full Text
View/download PDF

35. Biology of Melanoma Metastasis

Author

Ma, Qiaoli, Dieterich, Lothar C., Detmar, Michael, Fisher, David E., Section editor, Hayward, Nick, Section editor, Whiteman, David C., Section editor, Flaherty, Keith T., Section editor, Hodi, F. Stephen, Section editor, Tsao, Hensin, Section editor, Merlino, Glenn, Section editor, Fisher, David E., editor, and Bastian, Boris C., editor

Published
2019
Full Text
View/download PDF

36. Key Signaling Pathways in Normal and Neoplastic Melanocytes

Author

Aplin, Andrew E., Weeraratna, Ashani T., Fisher, David E., Section editor, Hayward, Nick, Section editor, Whiteman, David C., Section editor, Flaherty, Keith T., Section editor, Hodi, F. Stephen, Section editor, Tsao, Hensin, Section editor, Merlino, Glenn, Section editor, Fisher, David E., editor, and Bastian, Boris C., editor

Published
2019
Full Text
View/download PDF

37. Developmental Biology of Melanocytes

Author

Sommer, Lukas, Fisher, David E., Section editor, Hayward, Nick, Section editor, Whiteman, David C., Section editor, Flaherty, Keith T., Section editor, Hodi, F. Stephen, Section editor, Tsao, Hensin, Section editor, Merlino, Glenn, Section editor, Fisher, David E., editor, and Bastian, Boris C., editor

Published
2019
Full Text
View/download PDF

38. Ultraviolet Radiation and Melanoma

Author

Rünger, Thomas M., Fisher, David E., Section editor, Hayward, Nick, Section editor, Whiteman, David C., Section editor, Flaherty, Keith T., Section editor, Hodi, F. Stephen, Section editor, Tsao, Hensin, Section editor, Merlino, Glenn, Section editor, Fisher, David E., editor, and Bastian, Boris C., editor

Published
2019
Full Text
View/download PDF

41. A parathyroid hormone/salt-inducible kinase signaling axis controls renal vitamin D activation and organismal calcium homeostasis

Author

Yoon, Sung-Hee, Meyer, Mark B., Arevalo, Carlos, Tekguc, Murat, Zhang, Chengcheng, Wang, Jialiang S., Andrade, Christian D. Castro, Strauss, Katelyn, Sato, Tadatoshi, Benkusky, Nancy A., Lee, Seong Min, Berdeaux, Rebecca, Foretz, Marc, Sundberg, Thomas B., Xavier, Ramnik J., Adelmann, Charles H., Brooks, Daniel J., Anselmo, Anthony, Sadreyev, Ruslan I., Rosales, Ivy A., Fisher, David E., Gupta, Navin, Morizane, Ryuji, Greka, Anna, Pike, J. Wesley, Mannstad, Michael, and Wein, Marc N.

Subjects
Care and treatment, Development and progression, Genetic aspects, Health aspects, Cytochrome P-450 -- Health aspects, Parathyroid hormones -- Health aspects, Bone diseases -- Genetic aspects -- Development and progression -- Care and treatment, Cellular signal transduction -- Health aspects, Kidney diseases -- Genetic aspects -- Development and progression -- Care and treatment, Gene expression -- Health aspects, Parathyroid hormone -- Health aspects
Abstract

Introduction Vitamin D plays a critical role in bone and mineral metabolism and also controls other physiologic and pathophysiologic processes, including skeletal muscle function, reproductive health, cancer risk and progression, [...], The renal actions of parathyroid hormone (PTH) promote 1,25-vitamin D generation; however, the signaling mechanisms that control PTH-dependent vitamin D activation remain unknown. Here, we demonstrated that salt-inducible kinases (SIKs) orchestrated renal 1,25-vitamin D production downstream of PTH signaling. PTH inhibited SIK cellular activity by cAMP-dependent PKA phosphorylation. Whole-tissue and single-cell transcriptomics demonstrated that both PTH and pharmacologic SIK inhibitors regulated a vitamin D gene module in the proximal tubule. SIK inhibitors increased 1,25-vitamin D production and renal Cyp27b1 mRNA expression in mice and in human embryonic stem cell-derived kidney organoids. Global- and kidney-specific Sik2/Sik3 mutant mice showed Cyp27b1 upregulation, elevated serum 1,25- vitamin D, and PTH-independent hypercalcemia. The SIK substrate CRTC2 showed PTH and SIK inhibitor-inducible binding to key Cyp27b1 regulatory enhancers in the kidney, which were also required for SIK inhibitors to increase Cyp27b1 in vivo. Finally, in a podocyte injury model of chronic kidney disease-mineral bone disorder (CKD-MBD), SIK inhibitor treatment stimulated renal Cyp27b1 expression and 1,25-vitamin D production. Together, these results demonstrated a PTH/SIK/CRTC signaling axis in the kidney that controls Cyp27b1 expression and 1,25-vitamin D synthesis. These findings indicate that SIK inhibitors might be helpful for stimulation of 1,25-vitamin D production in CKD-MBD.

Published
2023
Full Text
View/download PDF

42. Biology of Melanocytes and Primary Melanoma

Author

Zaidi, M. Raza, Fisher, David E., Rizos, Helen, Balch, Charles M., editor, Atkins, Michael B., editor, Garbe, Claus, editor, Gershenwald, Jeffrey E., editor, Halpern, Allan C., editor, Kirkwood, John M., editor, McArthur, Grant A., editor, Thompson, John F., editor, and Sober, Arthur J., editor

Published
2020
Full Text
View/download PDF

43. Marty's last publication: A giant human being with a passion to cure children.

Author

Fisher, David E.

Subjects
*HUMAN biology, *RAS oncogenes, *KILLER cells, *NEVUS, *SQUARIC acid
Abstract

This article highlights the work of Martin C. Mihm, MD, in the field of pediatric dermatology, specifically his contributions to caring for children with birthmarks and vascular anomalies. It focuses on a project that aimed to develop mouse models for testing strategies to treat giant congenital melanocytic nevi (GCMN) without surgery. Mihm's expertise as a dermatopathologist and his dedication to helping children made him an invaluable collaborator on this project. The article also discusses the establishment of clinics and enhanced therapies for children with GCMNs, as well as the research conducted using genetically engineered mouse models. Overall, Mihm's passion and expertise greatly contributed to the success of this project. [Extracted from the article]

Published
2024
Full Text
View/download PDF

46. The state of melanoma: challenges and opportunities.

Author

Merlino, Glenn, Herlyn, Meenhard, Fisher, David E, Bastian, Boris C, Flaherty, Keith T, Davies, Michael A, Wargo, Jennifer A, Curiel-Lewandrowski, Clara, Weber, Michael J, Leachman, Sancy A, Soengas, Maria S, McMahon, Martin, Harbour, J William, Swetter, Susan M, Aplin, Andrew E, Atkins, Michael B, Bosenberg, Marcus W, Dummer, Reinhard, Gershenwald, Jeffrey E, Halpern, Allan C, Herlyn, Dorothee, Karakousis, Giorgos C, Kirkwood, John M, Krauthammer, Michael, Lo, Roger S, Long, Georgina V, McArthur, Grant, Ribas, Antoni, Schuchter, Lynn, Sosman, Jeffrey A, Smalley, Keiran S, Steeg, Patricia, Thomas, Nancy E, Tsao, Hensin, Tueting, Thomas, Weeraratna, Ashani, Xu, George, Lomax, Randy, Martin, Alison, Silverstein, Steve, Turnham, Tim, and Ronai, Ze'ev A

Subjects
Humans, Melanoma, Signal Transduction, Biomedical Research, Societies, Scientific, dormancy, early diagnosis, melanoma, metastasis, prevention, therapy, Cancer, Prevention, Vaccine Related, early diagnosis, Biological Sciences, Medical and Health Sciences, Dermatology & Venereal Diseases
Abstract

The Melanoma Research Foundation (MRF) has charted a comprehensive assessment of the current state of melanoma research and care. Intensive discussions among members of the MRF Scientific Advisory Council and Breakthrough Consortium, a group that included clinicians and scientists, focused on four thematic areas - diagnosis/early detection, prevention, tumor cell dormancy (including metastasis), and therapy (response and resistance). These discussions extended over the course of 2015 and culminated at the Society of Melanoma Research 2015 International Congress in November. Each of the four groups has outlined their thoughts as per the current status, challenges, and opportunities in the four respective areas. The current state and immediate and long-term needs of the melanoma field, from basic research to clinical management, are presented in the following report.

Published
2016

47. FOXD3 Regulates VISTA Expression in Melanoma

Author

Rosenbaum, Sheera R., Knecht, Meghan, Mollaee, Mehri, Zhong, Zhijiu, Erkes, Dan A., McCue, Peter A., Chervoneva, Inna, Berger, Adam C., Lo, Jennifer A., Fisher, David E., Gershenwald, Jeffrey E., Davies, Michael A., Purwin, Timothy J., and Aplin, Andrew E.

Published
2020
Full Text
View/download PDF

48. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

Author

Andrews, Miles C, Berry, Donald A, Block, Matthew S, Boland, Genevieve M, Bollin, Kathryn B, Carlino, Matteo S, Carvajal, Richard D, Cohen, Jonathan, Davar, Diwakar, Delman, Keith A, Dummer, Reinhard, Farwell, Michael D, Fisher, David E, Fusi, Alberto, Glitza, Isabella C, de Gruijl, Tanja D, Gyorki, David E, Hauschild, Axel, Hieken, Tina J, Larkin, James, Lawson, David H, Lebbe, Celeste, Lee, Jeffrey E, Lowe, Michael C, Luke, Jason J, McArthur, Grant A, McDermott, David F, McQuade, Jennifer L, Mitchell, Tara C, Petrella, Teresa M, Prieto, Peter A, Puzanov, Igor, Robert, Caroline, Salama, April K, Sandhu, Shaneen, Schadendorf, Dirk, Shoushtari, Alexander N, Sosman, Jeffrey A, Swetter, Susan M, Tanabe, Ken K, Turajlic, Samra, Tyler, Douglas S, Woodman, Scott E, Wright, Frances C, Zager, Jonathan S, Amaria, Rodabe N, Menzies, Alexander M, Burton, Elizabeth M, Scolyer, Richard A, Tetzlaff, Michael T, Antdbacka, Robert, Ariyan, Charlotte, Bassett, Roland, Carter, Brett, Daud, Adil, Faries, Mark, Fecher, Leslie A, Flaherty, Keith T, Gershenwald, Jeffrey E, Hamid, Omid, Hong, Angela, Kirkwood, John M, Lo, Serigne, Margolin, Kim, Messina, Jane, Postow, Michael A, Rizos, Helen, Ross, Merrick I, Rozeman, Elisa A, Saw, Robyn P M, Sondak, Vernon, Sullivan, Ryan J, Taube, Janis M, Thompson, John F, van de Wiel, Bart A, Eggermont, Alexander M, Davies, Michael A, Ascierto, Paolo A, Spillane, Andrew J, van Akkooi, Alexander C J, Wargo, Jennifer A, Blank, Christian U, Tawbi, Hussein A, and Long, Georgina V

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results